On August 27, Fosun Pharmaceutical announced that the veritumimab injection, which was approved by the holding subsidiary Yaoyou Pharmaceutical, has obtained conditional approval from the State Drug Administration for the treatment of adult patients with recurrent or refractory multiple myeloma who have received at least third-line treatment in the past. Fosun Pharmaceuticals added another major product to its hematoma pipeline, making it the first domestically produced original research BCMA×CD3 dual antibody to be approved.

On August 27, Fosun Pharmaceutical announced that the veritumimab injection, which was approved by the holding subsidiary Yaoyou Pharmaceutical, has obtained conditional approval from the State Drug Administration for the treatment of adult patients with recurrent or refractory multiple myeloma who have received at least third-line treatment in the past. Fosun Pharmaceuticals added another major product to its hematoma pipeline, making it the first domestically produced original research BCMA×CD3 dual antibody to be approved.